RxDoctor Payments Data

Laura Butch, NP

Nurse Practitioner · Grand Chute, WINPI 1952974206

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 118 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$708
  • Johnson & Johnson$369
  • E.r. Squibb & Sons, L.L.C.$241
  • Boston Scientific$177
  • Pfizer$157
  • Alnylam Pharmaceuticals Inc.$151
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,858 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,252
Medicare patients
170
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$112,363
EntrestoSacubitril/Valsartan37$30,527
XareltoRivaroxaban17$21,071
BrilintaTicagrelor19$15,848
JardianceEmpagliflozin12$13,080
Metoprolol Succinate93$1,812
Diltiazem 24hr Er (La)Diltiazem Hcl14$1,306
Bumetanide35$1,152
Diltiazem 24hr ErDiltiazem Hcl16$766
Spironolactone86$713
Potassium Chloride35$694
Isosorbide Mononitrate ErIsosorbide Mononitrate45$596
Atorvastatin Calcium32$543
Furosemide73$541
Losartan Potassium43$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$157$112,363120 claims
NovartisEntresto$708$30,52737 claims
Johnson & JohnsonXarelto$369$21,07117 claims
AstraZenecaBrilinta$88$15,84819 claims
Boehringer IngelheimJardiance$55$13,08012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Grand Chute

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →